OpenURL Connection Search

Select item for more details and to access through your institution.

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.
Published in:
Diabetes, Obesity & Metabolism, 2020, v. 22, n. 1, p. 30, doi. 10.1111/dom.13862
By:
- Koomen, Jeroen V.;
- Heerspink, Hiddo J. L.;
- Schrieks, Ilse C.;
- Schwartz, Gregory G.;
- Lincoff, A. Michael;
- Nicholls, Stephen J.;
- Svensson, Anders;
- Wedel, Hans;
- Weichert, Arlette;
- Grobbee, Diederick E.;
- Stevens, Jasper
Publication type:
Article
Model‐based approach for methoxy polyethylene glycol‐epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease.
Published in:
British Journal of Clinical Pharmacology, 2020, v. 86, n. 4, p. 801, doi. 10.1111/bcp.14186
By:
- Chanu, Pascal;
- Schaefer, Franz;
- Warady, Bradley A.;
- Schmitt, Claus Peter;
- Reigner, Bruno;
- Schnetzler, Gabriel;
- Meyer Reigner, Sylvie;
- Eisner, Mark;
- Weichert, Arlette;
- Frey, Nicolas
Publication type:
Article
Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
Published in:
2018
By:
- Stähli, Barbara E;
- Nozza, Anna;
- Schrieks, Ilse C;
- Buse, John B;
- Malmberg, Klas;
- Mellbin, Linda;
- Neal, Bruce;
- Nicholls, Stephen J;
- Rydén, Lars;
- Svensson, Anders;
- Wedel, Hans;
- Weichert, Arlette;
- Lincoff, A Michael;
- Grobbee, Diederick E;
- Tardif, Jean-Claude;
- Schwartz, Gregory G
Publication type:
journal article
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Published in:
2014
By:
- Lincoff, A Michael;
- Tardif, Jean-Claude;
- Schwartz, Gregory G;
- Nicholls, Stephen J;
- Rydén, Lars;
- Neal, Bruce;
- Malmberg, Klas;
- Wedel, Hans;
- Buse, John B;
- Henry, Robert R;
- Weichert, Arlette;
- Cannata, Ruth;
- Svensson, Anders;
- Volz, Dietmar;
- Grobbee, Diederick E;
- AleCardio Investigators
Publication type:
journal article
Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus.
Published in:
JAMA: Journal of the American Medical Association, 2014, v. 311, n. 15, p. 1515, doi. 10.1001/jama.2014.3321
By:
- Lincoff, A. Michael;
- Tardif, Jean-Claude;
- Schwartz, Gregory G.;
- Nicholls, Stephen J.;
- Rydén, Lars;
- Neal, Bruce;
- Malmberg, Klas;
- Wedel, Hans;
- Buse, John B.;
- Henry, Robert R.;
- Weichert, Arlette;
- Cannata, Ruth;
- Svensson, Anders;
- Volz, Dietmar;
- Grobbee, Diederick E.
Publication type:
Article
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
Published in:
2018
By:
- Schrieks, Ilse C.;
- Nozza, Anna;
- Stähli, Barbara E.;
- Buse, John B.;
- Henry, Robert R.;
- Malmberg, Klas;
- Neal, Bruce;
- Nicholls, Stephen J.;
- Rydén, Lars;
- Mellbin, Linda;
- Svensson, Anders;
- Wedel, Hans;
- Weichert, Arlette;
- Lincoff, A. Michael;
- Tardif, Jean-Claude;
- Grobbee, Diederick E.;
- Schwartz, Gregory G.
Publication type:
journal article

Found: 6

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.

Model‐based approach for methoxy polyethylene glycol‐epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease.

Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus.

Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.